论文部分内容阅读
人类乳头瘤病毒１６型（ＨＰＶ１６）在宫颈癌患者中检出率高达９０％。近年来通过基因工程方法对ＨＰＶ的晚期基因（Ｌ１和Ｌ２基因）编码的外壳蛋白产物的研究很多，发现主要壳蛋白（Ｌ１）可自我组装成病毒样颗粒（ｖｉｒｕｓ－ｌｉｋｅｐａｒｔｉｃｌｅｓ，ＶＬＰ），并可用作预防性疫苗；基于次要壳蛋白（Ｌ２）的预防性疫苗和核酸水平的预防性疫苗也很有前途。本文着重从近几年国际上ＨＰＶ１６预防性疫苗的基础性工作进展及预防性疫苗研究现状等方面及趋势作一综述。
Human papillomavirus type 16 (HPV16) has a detectable rate of up to 90% in patients with cervical cancer. In recent years, there have been many studies on the coat protein products encoded by the late genes (L1 and L2 genes) by genetic engineering and found that the major capsid protein (L1) can self-assemble into virus-like particles (VLPs) As a prophylactic vaccine; prophylactic vaccines based on prophylactic vaccines and nucleic acids based on the capsid protein (L2) are also promising. This article focuses on the recent progress in the international work on HPV16 preventive vaccines and preventive vaccines research status and other aspects and trends are reviewed.